Jim Mullen, former chief executive officer of Patheon, will lead DPx as chief executive officer, and it will be run as an independent company. DPx is the parent company that includes the business units Patheon, DSM Fine Chemicals, and Banner Life Sciences. DPx provides APIs and services for finished dosage drug products to pharma and biopharma companies, with a specialization in softgel formulations for OTC, prescription and nutritional consumer products through the Banner Life Sciences business.
Stefan Doboczky, member of the DSM managing board, said, “I am proud to witness the formation of DPx, a global CDMO, which will create substantial value for all stakeholders. With this partnership DSM made another major step implementing our strategy for our Pharma activities, growing via partnerships. Our customers will greatly benefit from DPx’s depth and breadth of capabilities and services.”
Paul S. Levy, managing director of JLL Partners, said, “This transaction is truly accretive with fundamental business logic. With DSM, JLL Partners has now created a global pharmaceutical contract manufacturer with the broadest product offering for our many and diverse customers. Our management team, representing the best talent from each company, is proven and completely committed to this enterprise. JLL is proud to have been chosen by DSM and we look forward to integrating the two businesses and building aggressively thereafter.”
“We are better positioned to add scale, new value chain capabilities and technologies, as well as expand our end-to-end service offerings to our customers,” said Mr. Mullen of DPx. “We will lead the way in changing how services are purchased by our customers and in doing so we will create value for our customers.”